In addition, DHM achieves synergistic relief of pain and depression symptoms by downregulating P2X7 receptor expression, blocking the ATP-gated ion channel-mediated ERK1/2 phosphorylation cascade, and reducing TNF-α and IL-1β levels (Silva et al., 2020). Here, MAPK3 is linked to depressive symptom measurement.